EMA starts rolling review of remdesivir for COVID-19

The CHMP’s decision to start the review is based on preliminary results from the Adaptive COVID-19 Treatment Trial (ACTT) study, which suggest a beneficial effect of remdesivir in the treatment of hospitalised patients with mild-to-moderate or severe COVID-19.

Source:

European Medicines Agency